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The physiological processes of angiogenesis, vasculogenesis and arteriogenesis contribute to the growth of collateral vessels
in response to obstructive arterial disease causing lower limb or myocardial ischaemia, but in clinical practice the
endogenous angiogenic response is often suboptimal or impaired, e.g. by factors such as ageing, diabetes or drug therapies.
Therapeutic angiogenesis is an application of biotechnology to stimulate new vessel formation via local administration of
pro-angiogenic growth factors in the form of recombinant protein or gene therapy, or by implantation of endothelial
progenitor cells that will synthesize multiple angiogenic cytokines. Numerous experimental and clinical studies have sought
to establish ‘proof of concept’ for therapeutic angiogenesis in PAD and myocardial ischaemia using different treatment
modalities, but the results have been inconsistent. This review summarises the mechanisms of angiogenesis and the results of
recent trials evaluating the efficacy and safety of different gene therapy, recombinant protein and cellular-based treatment
approaches to enhance collateral vessel formation.
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Introduction
The strengths and limitations of surgical revascular-
ization in peripheral arterial disease (PAD) are well
recognised. In general, by-pass grafting and percuta-
neous interventions are reserved for patients with
critical limb-threatening ischaemia and those with
disabling claudication due to discrete, proximal dis-
ease.1,2 This leaves a significant number of patients
with moderate-to-severe PAD with few, if any,
effective treatment options to improve symptoms,
restore distal perfusion and preserve tissue viability.
This particularly applies to patients with diffuse and
distal disease, who are often diabetic, and those who,
despite successful revascularization, present with
recurrent symptoms that are not amenable to further
surgical intervention.
There is good evidence that the development of
collateral vessels has a favourable effect on the
symptoms and outcomes of atherosclerotic disease.
For example, in acute myocardial infarction the
presence of a collateral circulation decreases infarct
size and improves left ventricular function and patient
survival.3 Over the last 10 years, there has been
considerable interest in the physiological mechanisms
that regulate new vessel formation.4 The main factors
that stimulate growth of collateral vessels are, firstly,
the duration and severity of ischaemia, as well as shear
stress and inflammation, but numerous local and
systemic cytokines also have pro- or anti-angiogenic
effects. Cancer researchers have been particularly
interested in blocking angiogenesis as a method of
inhibiting tumour growth; meanwhile, cardiovascular
researchers have explored the feasibility of enhancing
collateral vessel formation in patients with chronic
ischaemia of the myocardium or lower limb. This
review describes the underlying mechanisms and
principles of therapeutic angiogenesis, and summar-
ises important results from recent clinical and exper-
imental studies in PAD.
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Terminology Relating to New Vessel Formation
Angiogenesis is the sprouting of new capillaries from
existing vascular structures, a process that is triggered
by endothelial cell migration and proliferation. Remo-
delling of the extracellular matrix (ECM), tubule
formation and expansion of the surrounding vascular
tissues are key elements of angiogenesis (Fig. 1).
Vasculogenesis, however, is quite different: the in situ
formation of new blood vessels from circulating bone
marrow-derived endothelial progenitor cells (EPCs)
which differentiate into endothelial cells and fuse into
luminal structures. It was previously assumed that
vasculogenesis only occurred during embryological
development, but there is increasing evidence that
neovascularization in adult tissues involves both
processes of angiogenesis and vasculogenesis.5,6
Under normal conditions, the number of circulating
EPCs is relatively small but vascular trauma or
ischaemia results in mobilization and proliferation of
EPCs from the bone marrow.7 EPCs may contribute up
to 25% of endothelial cells in newly formed vessels,8
and there is evidence that the biological activity of
EPCs and vasculogenesis are impaired in conditions
such as diabetes.9
A more recently defined term, arteriogenesis, refers
to an increase in the calibre of pre-existing arteriolar
collateral connections by recruitment of perivascular
cells and expansion and remodelling of the extracellu-
lar matrix.10 Arteriogenesis increases the size and wall
thickness of collateral vessels, and shear stress (rather
than hypoxia) seems to be the main factor that
stimulates arteriogenesis.11 Thus, in response to
occlusion or stenosis of a major artery the haemody-
namic changes in proximal vessels lead to increased
blood flow through preformed collateral arterioles.
The associated increases in shear stress promote
arteriogenesis involving monocyte invasion of the
wall of the growing collateral arteriole.12 Migration of
circulating monocytes and their differentiation into
macrophages within the blood vessel wall is a key
element of arteriogenesis, together with recruitment
and expansion of smooth muscle cell and matrix
components of the vessel wall.
Thus, the initiation and development of new vessels
to provide an effective collateral circulation in occlu-
sive arterial disease involves all three processes of
angiogenesis, vasculogenesis and arteriogenesis.
Regulation of Angiogenesis
Initiation of angiogenesis requires the normally
quiescent vascular endothelium to become activated,
e.g. by ischaemia or circulating growth factors, which
trigger individual cells to break their intercellular
adhesions with neighbouring endothelial cells. One
‘leader cell’ then begins to migrate, followed by other
cells, in a process of capillary budding and endothelial
cell proliferation (Fig. 1). Local release of matrix
metalloproteinases (MMPs) and plasminogen
degrades the surrounding ECM while the migrating
endothelial cells form bands which develop into loops
and eventually canalize to allow blood to flow. The
new endothelial cells re-establish intercellular connec-
tions, and in the later stages of angiogenesis recruit-
ment of smooth muscle cells and fibroblasts creates
mature thicker-walled vessels (Fig. 1).
The key steps in angiogenesis—namely endothelial
cell activation, migration, proliferation and reorganis-
ation—are tightly regulated in a complex balance
between pro- and anti-angiogenic mechanisms. Over
the last 20–30 years, a large number of molecules have
been identified which either stimulate or inhibit
angiogenesis (Table 1). The most important pro-
angiogenic growth factors are vascular endothelial
growth factor (VEGF) (there are four spliced variants
of VEGF containing 121, 165, 189 and 206 amino
acids),13 and basic fibroblast growth factor (bFGF),
also known as FGF-2 (one of nine members of the FGF
family). VEGF is an endothelial cell specific mitogen
that is markedly upregulated by hypoxia,14 and plays
an important role in endothelial cell proliferation,
differentiation and survival. Platelets are a major
source of circulating VEGF,15 which interacts with
three tyrosine-kinase receptors (flt-1, flk-1 and flt-4) to
promote neovascularization and increased vascular
permeability. Production of a soluble form of the flt-1
receptor, s.flt-1, may be important in determining














VEGF, vascular endothelial growth factor; aFGF and bFGF, acid and
basic fibroblast growth factor (FGF-1 and FGF-2, respectively);
PDGF, platelet-derived growth factor; TGF, transforming growth
factor; TNF, tumour necrosis factor; HGF, hepatocyte growth factor;
PlGF, placental growth factor; TIMPs, tissue inhibitors of matrix
metalloproteinases.
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Fig. 1. Schematic showing the various stages in new vessel formation (including angiogenesis, vasculogenesis and
arteriogenesis). Ten individual steps are described in panels A to D showing endothelial cell (EC) proliferation andmigration
(angiogenesis) followed by extracellular matrix (ECM) remodelling and expansion of vascular smooth muscle (VSM) cells
(arteriogenesis).
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VEGF responses, and there is evidence that s.flt-1
production may be impaired in PAD.
FGFs, unlike VEGF, are non-secreted growth factors
that are released only during cell death or ischaemic
cell injury. FGFs are also powerful endothelial cell
mitogens, but the FGF family of cytokines is not
endothelial cell specific. At least four high-affinity FGF
receptors have been cloned and characterised. In vitro
studies have shown that FGF and VEGF have different
effects on the angiogenic process, e.g. FGF stimulates
vascular cells other than endothelial cells. In vivo the
inter-play between positive and negative regulators of
new vessel formation creates a complex microenvir-
onment that is often called the ‘angiogenic switch’.16,17
Cellular interactions are also very important in
determining the response of endothelial cells to
proliferate and migrate. There is evidence, for
example, that leucocytes and platelets exert important
effects on endothelial cells and angiogenesis either by
direct intercellular contact or via local release of
cytokines.4,18 Clinical and biochemical factors also
influence the formation of, and biological response to,
different angiogenic growth factors. For example,
hypoxia is one of the most potent inducers of
angiogenesis,17 principally via up-regulation of
VEGF,14 whereas diabetes and raised levels of choles-
terol and lipoprotein (a) are associated with a reduced
angiogenic response.19–21 Glycation of angiogenic
growth factors, e.g. bFGF, reduces their activity,22,23
while hypercholesterolaemia seems to affect angiogen-
esis indirectly via reduced nitric oxide (NO) avail-
ability.20
Although ischaemia activates physiological mech-
anisms leading to collateral vessel formation, there is
evidence that in clinical practice the endogenous
angiogenic response in patients with PAD is often
impaired or insufficient. For example, it has been
shown that angiogenesis is reduced in the elderly,24
and in patients with diabetes9,19,25 or dyslipidaemia.20
In addition, many of the commonly prescribed
cardiovascular drugs may also impair angiogenesis,
e.g. ACE inhibitors,26 statins27 and non-steroidal anti-
inflammatory drugs (NSAIDs).28 Conversely, physical
exercise enhances angiogenesis.29
Therapeutic angiogenesis aims to overcome any
limitations of the natural angiogenic response by
increasing substantially the local concentrations of
angiogenic growth factor(s) in the lower limb or
myocardium, either by administering recombinant
protein or the gene that codes for an angiogenic
growth factor, or by administering EPCs that will
synthesize a cocktail of growth factors in the vicinity of
new vessel formation.
Experimental Studies of Therapeutic Angiogenesis
in Animal Models of Lower Limb and Myocardial
Ischaemia
There has been considerable research into the phar-
macodynamics and pharmacokinetics of different
therapeutic interventions to increase levels of angio-
genic growth factors in animal models of lower limb
and myocardial ischaemia. These studies can broadly
be divided into three groups: (1) evaluation of different
angiogenic growth factors;30 – 38 (2) evaluation of
different treatment modalities and different routes of
administration, e.g. recombinant protein versus gene
transfer;39,40 and (3) studies evaluating cellular tech-
niques, including chemotactic methods to attract
monocytes to ischaemic tissues,41 local administration
of EPCs harvested from the peripheral circulation,42
and even autologous bone marrow transplantation to
provide EPCs capable of augmenting vasculogenesis
and synthesizing multiple angiogenic growth fac-
tors.43
Administration of recombinant protein
Several growth factors administered in the form of
recombinant proteins have been shown to augment
collateral vessel formation in vivo, e.g. VEGF is
effective in models of hindlimb and myocardial
ischaemia even after single dose administration.32–34
Similarly, there is good evidence that recombinant
bFGF produces dose-dependent increases in collateral
vessel formation, capillary density and blood flow in
animal models of intermittent claudication and stable
angina.35–37 Other recombinant angiogenic growth
factors also have therapeutic activity in experimental
models of PAD, e.g. hepatocyte growth factor (HGF)38
and placental growth factor.44
Gene transfer
Gene transfer is the introduction of foreign DNA into
target cells in order to achieve a localised, sustained
therapeutic over-expression of the chosen gene.
Several different approaches have been evaluated to
transfer an angiogenic growth factor gene into
vascular endothelial cells, but the success of any
technique depends upon the efficiency with which
the transgene is introduced and expressed within the
target cell population.45 Naked DNA is poorly taken-
up, but different types of DNA vectors have been
successfully used to increase the efficiency of gene
transfer. In cardiovascular research, the most com-
monly used vectors are either adenoviruses or
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plasmids, often formulated with liposomes to facilitate
the transfer of DNA across the cell membrane.
However, even the best methods of gene transfer still
encounter significant problems in achieving high
enough rates of transfection to result in clinically
significant levels of protein production.
Adenoviral vectors produce a higher efficiency of
gene transfer, but there is a risk of triggering an
immune response to the viral DNA. In addition, none
of the methods of gene transfer ensure that only the
target cells are transfected; introducing foreign DNA
into non-target cells may cause adverse effects. Thus,
more recently there has been considerable interest in
‘ex vivo gene transfer’—i.e. harvesting cells which are
then transfected in vitro before being replaced.46,47 This
method increases the transfection efficiency and
ensures that foreign DNA is only introduced into
target cells.
Several angiogenic genes have been evaluated in
experimental models of lower limb and myocardial
ischaemia, e.g. VEGF, bFGF, HGF and hypoxia
inducible factor (HIF)-1a. VEGF has been the most
intensively studied over the past 10 years, and several
studies have shown that gene transfer using naked
DNA or adenoviral vectors augments collateral
formation and tissue perfusion in models of myocar-
dial and hindlimb ischaemia.48–51 Unlike VEGF, bFGF
lacks a secretory signal sequence and is therefore not
actively secreted from cells following gene transfer.52
Thus, in order to achieve a clinical response the bFGF
gene would need to be modified to add a signal
sequence prior to transfection. This added difficulty
has resulted in less interest in developing gene transfer
methods for bFGF compared with VEGF, but limited
success has been reported with adenoviral and ex vivo
gene transfer of FGFs in animal models of myocardial
and hindlimb ischaemia.46,47,53
HGF has also shown some potential in gene transfer
studies in experimental animals, e.g. transfection of
naked DNA augmented collateral vessel growth in a
model of hindlimb ischaemia.54 HIF-1a is a transcrip-
tion factor that regulates the expression of several
genes encoding angiogenic proteins including VEGF
and its receptors. An active form of the transcription
factor has been synthesized and transferred effectively
in animal studies to induce collateral growth.55,56
Delivery of cells that express multiple angiogenic cytokines
There has always been a concern that angiogenesis
may be too complex a process to be stimulated
effectively by administration of a single angiogenic
cytokine, and therefore a separate line of research has
explored ways of increasing cellular recruitment with
a view to increasing local production of a cocktail of
growth factors. For example, there is evidence that
circulating monocytes play a crucial role in arteriogen-
esis,41 and that differentiation of monocytes into tissue
macrophages leads to local secretion of VEGF, nitric
oxide and angiogenic cytokines. Thus, in vitro studies
have shown that administration of monocyte che-
moattractant protein-1 (MCP-1), which increases the
recruitment of monocytes to ischaemic tissue,
improves collateral flow in a rabbit model of hindlimb
ischaemia.41,57
EPCs derived from bone marrow are present in the
peripheral circulation, and are mobilized and incor-
porated into sites of neovascularization in response to
tissue ischaemia.5 This has led to the investigation of
‘supply-side angiogenesis’ whereby EPCs are har-
vested from the bone marrow or peripheral blood,
expanded and concentrated ex vivo and then re-
administered into the lower limb of the animal.58,59
A further development of this technique involves
treating the EPCs with adenovirus-containing VEGF
or bFGF prior to re-implantation.60 The initial results
have shown augmented neovascularization and
increased perfusion in animal models of myocardial
and hindlimb ischaemia.60,61 Other cellular based
angiogenic techniques have evaluated bone marrow
derived mononuclear cells and embryonic stem
cells.62,63
Pharmacokinetic and pharmaceutical aspects of therapeutic
angiogenesis
There is uncertainty about the optimum method and
frequency of delivery of angiogenic growth factors,
whether in the form of recombinant protein or as gene
therapy. Ideally, the protein or gene therapy should be
easy to administer and produce a sustained, high local
concentration of the angiogenic cytokine with low
systemic availability. In practice, the i.v. or i.a. routes of
administration require massive doses in order to
achieve a localised therapeutic effect. This often results
in high systemic plasma concentrations and poten-
tially serious side effects.64 It has been shown that
administration of recombinant bFGF into a peripheral
vein is ineffective, whereas local i.a. injection achieves
higher local concentrations and a clear angiogenic
effect.65
In the case of gene transfer, transfection efficiency is
particularly poor when naked DNA is injected into the
circulation, probably because of degradation by
circulating nucleases. Nevertheless, animal studies
have shown a therapeutic effect following i.v. or i.a.
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injection of gene transfer vectors.34,66 Intramyocardial
injection is more effective in the heart,67 and gene
transfer by intramuscular injection has been successful
in increasing collateral growth in animal models of
PAD.50,55,68
Clinical Trials of Therapeutic Angiogenesis:
Theoretical Risks and Current Information on
Safety and Tolerability
A fairly large number of clinical studies have been
reported in the literature, ranging from uncontrolled
case reports to larger randomized controlled trials,
using several treatment modalities (e.g. recombinant
protein, gene transfer or cellular implantation) in
patients with PAD (Fontaine stages II and III) and
those with endstage myocardial ischaemia. These
studies have used a variety of treatments, patient
selection criteria and endpoints, as well as different
study designs and duration of therapy, therefore
meaningful comparisons are difficult and there is
very little scope to undertake combined analyses of
treatment efficacy. Establishing the safety of novel
treatments has been an early priority for clinical
studies.
Pharmacological stimulation of angiogenesis in
humans raises a number of theoretical concerns,
especially in relation to side effects in non-target
tissues, e.g. unwanted neovascularization, tumour
growth, haemorrhage from fragile new vessels, and
even an adverse effect on atherosclerotic plaques. In
addition, gene transfer techniques raise uncertainty
about the hazards of introducing foreign DNAwhich,
following intramuscular or intramyocardial injection,
may disturb muscle cell growth and turnover.69 The
possibility of causing vascular malformations was
illustrated in the first-ever report of VEGF gene
transfer for PAD; the patient concerned developed
three spider angiomas on the treated leg several weeks
after DNA administration.70
Triggering neovascularization in patients with
diabetic retinopathy has been another major concern,
particularly since VEGF plays an important role in
new vessel formation around the optic disc and in
sight-threatening macular oedema.71 Most clinical
studies of therapeutic angiogenesis have included
fundoscopic surveillance and so far no significant
adverse effects have been reported in the eye72,73 but
several studies have excluded patients with pre-
existing diabetic retinopathy (even the common form
of background retinopathy). Given that patients with
diabetes are an important subgroup that may benefit
from therapeutic angiogenesis more safety data are
required in this population.
A number of growth factors are important in
tumourigenic angiogenesis, which raises concerns
that underlying polyps, tumours and various benign
abnormalities might be activated, or develop compli-
cations, as a result of systemic exposure to high
pharmacological doses of angiogenic cytokines. These
concerns are plausible and difficult to exclude,
although no serious tumour-related side effects have
emerged in clinical trials to date. In fact, in the recent
VIVA trial, there were more new diagnoses of
malignant disease in the control group.74 Angiogenic
growth factors may also stimulate neovascularization
within the intima of the arterial wall and at sites of
atherosclerotic disease, potentially causing plaque
instability and plaque rupture due to intimal neovas-
cularization.75 The limited results of clinical trials,
however, seem to refute this possibility, and indeed, by
contrast, suggest that angiogenic factors inhibit neoin-
timal thickening.76
Administration of high systemic concentrations of
VEGF (also known as vascular permeability factor) has
the potential to cause hypotension and oedema. These
side effects have been reported in trials of recombinant
VEGF, but seem to be relatively mild, transient and
reversible.74,77 In the case of recombinant bFGF, the
main adverse effects are on the kidney, especially
proteinuria.78 Modest increases in urinary albumin
excretion rate have been reported in several studies
following single or double doses of bFGF, but one trial
of repeated intravenous infusions of bFGF was
terminated because of severe proteinuria in five out
of 24 patients.79
Notwithstanding the potential hazards of gene
transfer,69 one major advantage of this technique is
that systemic plasma concentrations of the gene
product do not increase,80,81 i.e. the therapeutic effect
is very well contained locally. Gene therapy, however,
may provoke an unwanted inflammatory response.
Several studies have reported transient fevers follow-
ing the procedure, especially with adenoviral vec-
tors.81,82 In one randomized controlled trial, 61% of
patients developed adenoviral antibodies which may
have important limitations for the feasibility of giving
repeated treatments.82
Most clinical studies to-date have been relatively
short (2 weeks to 1 year follow-up), but two recent
trials have provided longer-term safety data. Firstly,
outcomes up to 3 years after administration of bFGF
via perivascular beads at the time of coronary artery
bypass grafting showed two late deaths in the highest
dose group, one from pancreatic carcinoma and one
sudden death of unknown cause.83 There were no
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differences in overall mortality between the actively
treated and control groups, and no other longer term
serious adverse events.83 Secondly, a trial of gene
transfer of VEGF using plasmid-liposome and adeno-
viral vectors for critical limb ischaemia and intermit-
tent claudication has reported safety data up to 2
years. There have been no differences in mortality, and
no new tumours detected.82
Clinical Trials of Therapeutic Angiogenesis in
Lower Limb Ischaemia: Information About
Treatment Efficacy
Following the first case report of therapeutic angio-
genesis in 1996, VEGF gene transfer in a patient with
critical limb ischaemia,70 there have been numerous
clinical studies of different angiogenic agents in both
PAD and inoperable myocardial ischaemia. The
results have been inconsistent, and several studies
were not adequately controlled or powered to make
firm conclusions about treatment efficacy. Further-
more, it has been particularly difficult to undertake a
combined meta-analysis because the various studies
have used different treatment modalities, endpoints
and inclusion/exclusion criteria. The placebo effect in
cardiovascular interventions should not be under-
estimated, yet several clinical studies, for obvious
practical reasons, were not fully blinded or did not
include a properly matched control group. More
recently, however, some larger multicentre random-
ized controlled trials have been published.
Clinical trials in patients with ischaemic heart disease:
lessons about safety and trial design that are relevant to
future prospects in PAD
There have been several (mostly small and uncon-
trolled) clinical studies of therapeutic angiogenesis in
patients with endstage myocardial ischaemia (Table 2).
The early results using intramyocardial VEGF gene
transfer and intra-coronary injection of bFGF protein
showed encouraging improvements in anginal fre-
quency and angiographic scores of collateral
growth,72,76,77,84–87 but less impressive results have
appeared from larger multicentre randomized con-
trolled trials74,80,81,88 (Table 2). Changes in surrogate
endpoints, such as myocardial perfusion imaging or
angiography, are much less clinically relevant than
differences in anginal frequency or exercise tolerance.
Thus, recent larger clinical trials have included the
Seattle Angina Questionnaire (SAQ) and other quality
of life indices.74,88
The three largest muticentre randomized controlled
trials, i.e. the FIRST,88 VIVA74 and KAT II81 studies,
have been fairly disappointing. The FIRST trial, for
example, evaluated the effects of intracoronary recom-
binant bFGF in over 330 patients. Although angina
symptom scores were significantly improved after 90
days, treadmill exercise tolerance and myocardial
perfusion were no different between the two groups.88
Similarly, the VIVA and KAT II trials used recombinant
VEGF and VEGF gene transfer, respectively, and there
were only modest, inconsistent improvements in
isolated endpoints.74,81
Clinical trials in patients with critical limb ischaemia
The initial studies of therapeutic angiogenesis in PAD
were conducted in patients with critical limb ischae-
mia (Table 3). These were patients who were either
unsuitable for surgical revascularization, or those who
had failed other treatment options and were at high
risk of distal amputation. Case reports and small
uncontrolled studies appeared to show dramatic
benefits. For example, VEGF gene transfer was
successful in achieving clinical improvement (e.g.
resolution of rest pain), increased density of collateral
vessels and increased ABPI69,73,89,90 (Fig. 2). However,
in a larger randomized controlled trial of VEGF gene
therapy, 87% of patients showed improved vascularity
on digital subtraction angiography but there were no
significant differences between the treatment and
placebo groups in terms of restenosis after angioplasty,
amputation rates, ulcer healing or severity of rest
pain.82 A further uncontrolled study using a plasmid
vector for VEGF gene transfer has shown an 83%
improvement in rest pain and 75% improvement in
ulcer healing, but the number of patients is too small to
draw firm conclusions.73
There is considerable interest in cellular based
therapy for improving lower limb outcomes in critical
ischaemia. For example, in the TACT study, a
randomized controlled trial, autologous implantation
of bone marrow mononuclear cells, including EPCs,
into critically ischaemic limbs produced clinical
improvements in rest pain in 39 out of 45 patients. In
addition, limbs injected with bone marrow mono-
nuclear cells showed a significant increase in ABPI
(.0.1) in 31 out of 45 patients, from 0.35 at baseline to
0.47 after 4 weeks ðp , 0:001Þ:91 Treadmill walking
time also improved (1.6–5.0 min, p , 0:001), and
ischaemic ulcers were healed in 21 out of 28 patients.91
The investigators in the TACT study used peripheral
blood mononuclear cells with 500-fold fewer EPCs as
the placebo control.
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Table 2. Summary of all published clinical studies of therapeutic angiogenesis in patients with myocardial ischaemia
Ref. Treatment No. of Subjects Follow up Outcomes
Active Control Safety Endpoints Results
84 Intra-myocardial VEGF gene 5 — 60 days No SAEs Angina frequency Improved
Myocardial perfusion Improved ðp , 0:05Þ
Angiography Improved collateral flow
85 Perivascular beads bFGF protein 16 8 3 years 2 deaths: 1 in control 1 in active Angina frequency Treatment group angina free
Myocardial perfusion Improved with high dose ðp ¼ 0:01Þ
86 Intra-myocardial VEGF gene 21 — 2 months 3 deaths Angina class Improved class
Angiography Improved collateral scores
Treadmill exercise Improved in 50%
76 Intra-coronary VEGF gene 10 5 6 months No SAEs Angiography No improvement at 6 months
72 Intra-coronary bFGF protein 52 — 6 months Mortality 8% hypotension proteinuria Angina questionnaire Improvement ðp , 0:001Þ
LV ejection fraction Small improvement
MR imaging Improved ðp , 0:001Þ
77 Intra-Coronary VEGF protein 15 — 60 days Hypotension flushing Angina class Improvement ðp ¼ 0:002Þ
Myocardial perfusion Improved in 50%
87 Intra-myocardial VEGF gene 12 7 12 weeks No SAEs Angina class Improved ðp ¼ 0:04Þ
Treadmill exercise Improved ðp ¼ 0:02Þ
FIRST 88 Intra-coronary bFGF protein 251 86 180 days No difference in mortality/SAEs Angina questionnaire Improved at 90 days ðp ¼ 0:035Þ
Myocardial perfusion No difference
Treadmill exercise No difference
AGENT 80 Intra-coronary FGF-4 gene 60 19 10 months No difference in mortality/SAEs Treadmill exercise Improved compared to placebo
Stress echo No difference from baseline
VIVA 74 IV þ Intra-coronary VEGF protein 115 63 120 days Hypotension flushing Angina questionnaire Improvement at 120 days ðp ¼ 0:09Þ
Myocardial perfusion No improvement
Treadmill exercise Improved at 120 days ðp ¼ 0:15Þ
KAT II 81 Intra-coronary VEGF gene 65 38 6 months No difference in mortality/SAEs Re-stenosis rate No difference from placebo














































Table 3. Summary of all published clinical studies of therapeutic angiogenesis in patients with PAD
Ref. Treatment No. of subjects Follow up Outcomes
Active Control Safety Endpoints Results
70 Intra-arterial VEGF165 Gene 1 — 12 weeks 3 angiomas Angiography Increased collaterals
89 Intra-Muscular VEGF165 Gene 6 — 14 months No SAEs ABPI Increased in 4 limbs
Angiography New collaterals
90 Intra-Muscular VEGF165 Gene 9 — 6 months Transient oedema ABPI Increased ðp ¼ 0:028Þ
Angiography Increased collaterals
Symptoms Reduced rest pain ðp ¼ 0:043Þ
78 Intra-arterial bFGF Protein 13 6 1 year Mild proteinuria Calf blood flow Improved ðp , 0:05Þ
Symptoms Some improvement
79 IV bFGF Protein 16 8 — Severe proteinuria None Study stopped prematurely. No positive results at cessation
92 TRAFFIC Intra-arterial bFGF Protein 127 63 6 months Proteinuria Peak walking time Increased at 90 days ðp ¼ 0:034Þ
ABPI Increased at 90 days ðp ¼ 0:037Þ
82 Intra-arterial VEGF Gene 35 19 2 years No SAEs Angiography Improved vascularity ðp ¼ 0:03Þ
ABPI No difference
Symptoms No difference
Re-stenosis rate No difference
73 Intra-Muscular VEGF165 Gene 24 — 6 months Transient oedema ABPI Improved ðp , 0:001Þ
Angiography Increased collaterals ðp , 0:01Þ
Symptoms Reduced rest pain and ulcer healing

















































Clinical trials in patients with intermittent claudication
Two randomized, placebo-controlled trials have
recently been reported in patients with intermittent
claudication.92,93 Both were phase II ‘proof of concept’
studies, one using intra-arterial recombinant bFGF92
and the other using intra-muscular adenoviral gene
transfer of VEGF121.
93
The TRAFFIC study was a randomized, double-
blind placebo-controlled trial of single or repeat-dose
i.a. recombinant bFGF 30 mg/kg.92 The formulation of
bFGF used in this study was a 146-amino acid, non-
glycosylated, monomeric 16.5 kDa protein which is
produced in genetically engineered yeast. The dose
(30 mg/kg) was the maximum-tolerated dose of bFGF
(limited by acute hypotension) in a phase 1 study of
intracoronary perfusion.72
Patients with intermittent claudication and repro-
ducible exercise tolerance on a treadmill received half
the dose of bFGF down each femoral artery via a single
arterial puncture and crossover catheter. Patients
needed two reproducible (within 20%) Gardner tread-
mill tests (with peak walking time between 1 and
12 min) during a 30-day screening period in order to
be eligible for inclusion. Other inclusion criteria
included evidence of infra-inguinal obstructive arter-
ial disease (.70% stenosis of femoral, popliteal, or
tibial arteries on angiography) and a resting APBI
,0.8 on the most affected limb. All patients received
appropriate medical management and risk factor
modification. Anyone with a history of malignancy
within the past 10 years was excluded, as were those
with other exercise limiting symptoms, e.g. arthritis or
angina. A total of 377 patients were screened for the
TRAFFIC study, and 190 were deemed eligible for
randomization.
Patients were randomized to placebo, single-dose
bFGF or two doses of bFGF (a second dose 30 days
later). Clinical and demographic details were similar
in the three groups (e.g. mean ages 65–69 years; 24–
38% were current smokers; 33% were diabetic; and
half had undergone previous revascularization for
PAD). Most patients (85%) had femoropopliteal dis-
ease; 30% had isolated femoropopliteal disease and
45–55% had multiple sites of disease in the femor-
opopliteal region. Two-thirds of patients had evidence
of bilateral disease.
The maximum walking distance at 90 days was the
primary endpoint for the TRAFFIC study, and there
were results for over 60 patients in each of the three
treatment groups. The trial reported a statistically
significant improvement in peak walking time, but
there was no difference between single and repeated
doses of bFGF: for example, compared with baseline
patients in the placebo group increased peak walking
time by 0.60 min (14%), patients in the single-dose
group increased this time by 1.77 min (34%), and
patients in the double-dose group increased by
1.54 min (20%) (Fig. 3). Results of the intention-to-
treat analysis ðn ¼ 190Þ showed a significant difference
between the three groups ðp ¼ 0:034Þ: Active therapy
also produced a small but significant increase in ABPI
in the more affected limb ðp , 0:04Þ:92 However,
patients with non-compressible vessels ðn ¼ 10Þ and
those who withdrew from the study early ðn ¼ 14Þ or
who were revascularized ðn ¼ 4Þ were excluded from
this analysis.
Three subgroups (smoking, diabetes and older age)
Fig. 2. Ankle-brachial pressure index (ABPI) before and after plasmid-mediated VEGF165 gene transfer in 24 limbs of 21
patients with rest pain and chronic critical limb ischaemia. Doses varying between 400 and 2000 mg of ph VEGF165 were
injected intra-muscularly into the affected limbs, and a repeat dose administered 4 weeks later. Results show the change in
ABPI following VEGF. Reproduced from an uncontrolled study, with permission.73
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were prespecified in the TRAFFIC study because of
their potential to influence the primary endpoint.
Diabetes, age greater than median (68 years), and non-
current smoking status were all associated with lower
improvement in peak walking time in response to
bFGF; however, only smoking status had an indepen-
dent effect on peak walking time. Current smokers
showed a greater increase in peak walking time (1.25,
2.10, and 2.26 min for placebo, single-dose and double-
dose, respectively).92
One or two doses of bFGF was generally well
tolerated in the TRAFFIC study. Transient acute
hypotension was uncommon: two patients in the
placebo group (3%), four in the single-dose group
(6%) and five in the double-dose group (8%). Corre-
sponding frequencies for development of proteinuria
were 3% (placebo), 9% (single-dose) and 11% (double-
dose). Seven out of nine patients who developed
proteinuria also had diabetes. There were two deaths
(one in placebo group and one in double-dose group)
during the study. There was no evidence of tumour-
igenesis or adverse effects on the retina with bFGF
administration.
The RAVE trial was also a phase II multicentre,
randomized, placebo-controlled, double-blind study
to evaluate the safety and efficacy of AdVEGF121, a
replication-deficient adenovirus encoding the 121-
amino-acid isoform of VEGF.93 In total 105 patients
with unilateral exercise-limiting intermittent claudica-
tion were randomized after a run-in phase to establish
that they had reproducible exercise performance on a
treadmill (peak walking time 1–10 min). Patients were
stratified by diabetes status and randomized to low-
dose AdVEGF121, high-dose AdVEGF121 or placebo,
administered as 20 intramuscular injections to the
index leg in a single session. Over 105 patients were
entered in the study, which gave .80% power to
detect a difference of 1.5 min in peak walking time.94
The results showed no significant difference in the
primary endpoint, change in peak walking time after
12 weeks: e.g. mean values of 1.8 ^ 3.2 min (placebo)
vs. 1.6 ^ 1.9 min (low-dose AdVEGF121) vs.
1.5 þ 3.1 min (high-dose AdvEGF121).93 Secondary
endpoints, including ABPI and quality of life
measures, were also unchanged after 12 and 26
weeks. The adenoviral therapy was associated with
peripheral oedema.93
Possible Explanations for Clinical Trial Results
Being Inconsistent and Inconclusive
The randomized controlled clinical trials in PAD have
produced results that are less consistent than those
undertaken in animals and less impressive in terms of
the absolute treatment effect. This discrepancy raises
the possibility that, in the in vivo clinical situation of
patients with vascular disease, it is the responsiveness
to angiogenic stimuli that is impaired rather than a
problem with the availability of angiogenic growth
factors. For example, increased (not decreased) levels
of VEGF have been reported in PAD,95 which could be
interpreted as evidence of a potential defect in VEGF
responsiveness. Differences in the production of
soluble flt-1 may account for inter-subject differences
in VEGF effects. In addition, it is possible that
angiogenesis is abnormal in some way in patients
with PAD. Both of these possibilities might explain
why supplementing the availability of angiogenic
growth factors does not necessarily augment angio-
genesis in patients with arterial disease. The animal
models used in various experimental studies often do
not have on-going vascular disease and therefore may
not mimic the clinical problem of reduced angiogenic
responsiveness.
Conclusion
The formation of new blood vessels, including
collaterals, is a complex physiological process that
occurs in adults in response to tissue injury or
ischaemia. Neovascularization involves angiogenesis,
vasculogenesis and arteriogenesis, and there are
several pro- and anti-angiogenic cytokines that regu-
late endothelial cell migration and proliferation. The
endogenous angiogenic response seems to be
impaired and/or insufficient in patients with PAD or
Fig. 3. Results from the TRAFFIC study. Improvement in
peak walking time (PWT) 90 days after treatment with intra-
arterial placebo ðn ¼ 58Þ; single-dose bFGF ðn ¼ 62Þ or
double-dose bFGF ðn ¼ 54Þ in patients with intermittent
claudication. Single dose vs. placebo, p ¼ 0:026; double-dose
vs. placebo, p ¼ 0:45: Reproduced with permission.92
Therapeutic Angiogenesis in PAD 19
Eur J Vasc Endovasc Surg Vol 28, July 2004
myocardial ischaemia, and therefore therapeutic
angiogenesis seeks to augment collateral vessel for-
mation using local administration of recombinant
proteins or genes for angiogenic growth factors, or
by re-implantation of EPCs harvested from the bone
marrow or peripheral circulation.
VEGF is a secreted, endothelial cell specific mito-
gen, whereas the family of FGFs, especially bFGF, are
not secreted but stimulate non-endothelial cell types in
the angiogenic process. Experimental and clinical
studies have evaluated the effects of VEGF gene
transfer and recombinant bFGF in animals and
humans with critical limb ischaemia, intermittent
claudication and endstage myocardial ischaemia.
Although the early uncontrolled reports were highly
encouraging, more recent results from multicentre
randomized controlled trials have been far less
convincing. In intermittent claudication, intra-arterial
recombinant bFGF improved peak walking time at 90
days in the TRAFFIC study92 but VEGF121 gene
transfer was ineffective in the RAVE trial.93 In critical
limb ischaemia, autologous bone marrow transplan-
tation was effective in a randomized controlled trial.91
There is still much to learn about the optimum
treatment modality, dosing frequency and route of
administration, but intra-arterial recombinant protein
therapy is closer to being available for routine use than
gene therapy. It is becoming clear that trials of single
angiogenic growth factors are not achieving the results
anticipated from experimental studies, and therefore
administration of multiple agents may be necessary to
optimize the angiogenic response.96 For example, the
combination of VEGF and bFGF has synergistic
effects.97 If regulatory approval is ever granted for
these novel (and no doubt expensive) technologies,
therapeutic angiogenesis is likely to be reserved for
those patients with severe limb-threatening PAD that
is not suitable or has failed with conventional
revascularization. Whether a one-off intervention at
such an advanced stage can achieve sufficient reperfu-
sion, in a short space of time, to avert amputation is
uncertain.
Thus, can biotechnology produce an effective
collateral circulation? At present, this seems more
remote than it did perhaps 3 years ago when
experimental studies were so encouraging. Angiogen-
esis is clearly complex, and it may be necessary to
adopt a therapeutic strategy that has several com-
ponents to improve angiogenic responsiveness as well
as increasing the availability of angiogenic growth
factors.
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